125 related articles for article (PubMed ID: 32489121)
21. Predictive value of tumor-infiltrating lymphocytes for response to neoadjuvant chemotherapy and breast cancer prognosis.
Li X; Tan Q; Li H; Yang X
J Surg Oncol; 2021 Jan; 123(1):89-95. PubMed ID: 33047336
[TBL] [Abstract][Full Text] [Related]
22. Risk-Adapted Adjuvant Chemotherapy After Concomitant Fluoropyrimidine-Radiotherapy Neoadjuvant Treatment for Patients With Resectable CT3-4 or N+ Rectal Cancer: Five-Year Disease-Free Survival Results of a Single-Center Series.
Sastre J; Serrano JJ; Fernández C; Ramirez C; Ortega L; García-Paredes B; Corona J; Alfonso R; Córdoba S; Díaz-Rubio E
Clin Colorectal Cancer; 2016 Jun; 15(2):128-34. PubMed ID: 26385572
[TBL] [Abstract][Full Text] [Related]
23. Prognostic Significance of Tumor-Infiltrating Lymphocytes in Patients With Pancreatic Ductal Adenocarcinoma Treated With Neoadjuvant Chemotherapy.
Nejati R; Goldstein JB; Halperin DM; Wang H; Hejazi N; Rashid A; Katz MH; Lee JE; Fleming JB; Rodriguez-Canales J; Blando J; Wistuba II; Maitra A; Wolff RA; Varadhachary GR; Wang H
Pancreas; 2017 Oct; 46(9):1180-1187. PubMed ID: 28902789
[TBL] [Abstract][Full Text] [Related]
24. Nucleotide excision repair protein ERCC1 and tumour-infiltrating lymphocytes are potential biomarkers of neoadjuvant platinum resistance in high grade serous ovarian cancer.
Scurry J; van Zyl B; Gulliver D; Otton G; Jaaback K; Lombard J; Vilain RE; Bowden NA
Gynecol Oncol; 2018 Nov; 151(2):306-310. PubMed ID: 30194007
[TBL] [Abstract][Full Text] [Related]
25. Association of tumor-infiltrating lymphocytes with distant disease-free survival in the ShortHER randomized adjuvant trial for patients with early HER2+ breast cancer.
Dieci MV; Conte P; Bisagni G; Brandes AA; Frassoldati A; Cavanna L; Musolino A; Giotta F; Rimanti A; Garrone O; Bertone E; Cagossi K; Sarti S; Ferro A; Piacentini F; Maiorana A; Orvieto E; Sanders M; Miglietta F; Balduzzi S; D'Amico R; Guarneri V
Ann Oncol; 2019 Mar; 30(3):418-423. PubMed ID: 30657852
[TBL] [Abstract][Full Text] [Related]
26. Prognostic relevance of programmed cell death-ligand 1 expression and CD8+ TILs in rectal cancer patients before and after neoadjuvant chemoradiotherapy.
Chen TW; Huang KC; Chiang SF; Chen WT; Ke TW; Chao KSC
J Cancer Res Clin Oncol; 2019 Apr; 145(4):1043-1053. PubMed ID: 30874889
[TBL] [Abstract][Full Text] [Related]
27. Predictive and Prognostic Role of Tumor-Infiltrating Lymphocytes for Early Breast Cancer According to Disease Subtypes: Sensitivity Analysis of Randomized Trials in Adjuvant and Neoadjuvant Setting.
Carbognin L; Pilotto S; Nortilli R; Brunelli M; Nottegar A; Sperduti I; Giannarelli D; Bria E; Tortora G
Oncologist; 2016 Mar; 21(3):283-91. PubMed ID: 26865589
[TBL] [Abstract][Full Text] [Related]
28. Chemosensitivity, tumor infiltrating lymphocytes (TILs), and survival of postpartum PABC patients treated by neoadjuvant chemotherapy.
Labrosse J; Abdennebi I; Thibault L; Laas E; Merckelbagh H; Morel C; Lam T; Lae M; Reyal F; Hamy AS
Breast; 2018 Dec; 42():61-67. PubMed ID: 30179779
[TBL] [Abstract][Full Text] [Related]
29. Adjuvant treatment combining cellular immunotherapy with chemotherapy improves the clinical outcome of patients with stage II/III gastric cancer.
Wang Y; Wang C; Xiao H; Niu C; Wu H; Jin H; Yao C; He H; Tian H; Han F; Li D; Han W; Xu J; Chen J; Cui J; Li W
Cancer Med; 2017 Jan; 6(1):45-53. PubMed ID: 27790867
[TBL] [Abstract][Full Text] [Related]
30. Relevance of tumour-infiltrating lymphocytes, PD-1 and PD-L1 in patients with high-risk, nodal-metastasised breast cancer of the German Adjuvant Intergroup Node-positive study.
Noske A; Möbus V; Weber K; Schmatloch S; Weichert W; Köhne CH; Solbach C; Ingold Heppner B; Steiger K; Müller V; Fasching P; Karn T; van Mackelenbergh M; Marmé F; Schmitt WD; Schem C; Stickeler E; Loibl S; Denkert C
Eur J Cancer; 2019 Jun; 114():76-88. PubMed ID: 31075727
[TBL] [Abstract][Full Text] [Related]
31. A nomogram to predict pathologic complete response (pCR) and the value of tumor-infiltrating lymphocytes (TILs) for prediction of response to neoadjuvant chemotherapy (NAC) in breast cancer patients.
Hwang HW; Jung H; Hyeon J; Park YH; Ahn JS; Im YH; Nam SJ; Kim SW; Lee JE; Yu JH; Lee SK; Choi M; Cho SY; Cho EY
Breast Cancer Res Treat; 2019 Jan; 173(2):255-266. PubMed ID: 30324273
[TBL] [Abstract][Full Text] [Related]
32. Prognostic value of tumor suppressors in osteosarcoma before and after neoadjuvant chemotherapy.
Robl B; Pauli C; Botter SM; Bode-Lesniewska B; Fuchs B
BMC Cancer; 2015 May; 15():379. PubMed ID: 25956431
[TBL] [Abstract][Full Text] [Related]
33. Tumor-infiltrating CD8+ and FOXP3+ lymphocytes before and after neoadjuvant chemotherapy in cervical cancer.
Liang Y; Lü W; Zhang X; Lü B
Diagn Pathol; 2018 Nov; 13(1):93. PubMed ID: 30474571
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of the Predictive and Prognostic Values of Stromal Tumor-Infiltrating Lymphocytes in HER2-Positive Breast Cancers treated with neoadjuvant chemotherapy.
Yang X; Rao J; Yang W; Shui R
Target Oncol; 2018 Dec; 13(6):757-767. PubMed ID: 30406444
[TBL] [Abstract][Full Text] [Related]
35. TIM3 expression on TILs is associated with poor response to neoadjuvant chemotherapy in patients with locally advanced triple-negative breast cancer.
Cabioglu N; Onder S; Oner G; Karatay H; Tukenmez M; Muslumanoglu M; İgci A; Eralp Y; Aydiner A; Saip P; Yavuz E; Ozmen V
BMC Cancer; 2021 Apr; 21(1):357. PubMed ID: 33823818
[TBL] [Abstract][Full Text] [Related]
36. Predictive and prognostic value of stromal tumour-infiltrating lymphocytes before and after neoadjuvant therapy in triple negative and HER2-positive breast cancer.
Ochi T; Bianchini G; Ando M; Nozaki F; Kobayashi D; Criscitiello C; Curigliano G; Iwamoto T; Niikura N; Takei H; Yoshida A; Takei J; Suzuki K; Yamauchi H; Hayashi N
Eur J Cancer; 2019 Sep; 118():41-48. PubMed ID: 31302586
[TBL] [Abstract][Full Text] [Related]
37. Adjuvant radiation therapy in resected high-grade localized skeletal osteosarcomas treated with neoadjuvant chemotherapy: Long-term outcomes.
Sole CV; Calvo FA; Alvarez E; Cambeiro M; Cuervo M; San Julian M; Sole S; Martinez-Monge R; Sierrasesumaga L
Radiother Oncol; 2016 Apr; 119(1):30-4. PubMed ID: 26970678
[TBL] [Abstract][Full Text] [Related]
38. Stromal ColXα1 expression correlates with tumor-infiltrating lymphocytes and predicts adjuvant therapy outcome in ER-positive/HER2-positive breast cancer.
Zhao CL; Singh K; Brodsky AS; Lu S; Graves TA; Fenton MA; Yang D; Sturtevant A; Resnick MB; Wang Y
BMC Cancer; 2019 Nov; 19(1):1036. PubMed ID: 31675929
[TBL] [Abstract][Full Text] [Related]
39. Neoadjuvant vs. adjuvant chemotherapy for cholangiocarcinoma: A propensity score matched analysis.
Yadav S; Xie H; Bin-Riaz I; Sharma P; Durani U; Goyal G; Borah B; Borad MJ; Smoot RL; Roberts LR; Go RS; McWilliams RR; Mahipal A
Eur J Surg Oncol; 2019 Aug; 45(8):1432-1438. PubMed ID: 30914290
[TBL] [Abstract][Full Text] [Related]
40. Proximal tumor location and fluid-fluid levels on MRI predict resistance to chemotherapy in stage IIB osteosarcoma.
Jeon DG; Song WS; Cho WH; Kong CB; Cho SH
Clin Orthop Relat Res; 2014 Jun; 472(6):1911-20. PubMed ID: 24574120
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
